Issue of Equity (2848H)

TIDMATD

RNS Number : 2848H

Asterand PLC

25 May 2011

 
 For Immediate Release   25 May 2011 
 

Asterand plc

("Asterand" or "the Company")

Issue of Equity

Asterand PLC (LSE: ATD) announces that it has issued and allotted, conditional only on admission to listing on the UKLA's Official List and to trading on the London Stock Exchange, a total of 2,572,140 Ordinary Shares of 5 pence each ("ordinary shares"), pursuant to the exercise of share options under the Company's Long Term Incentive Plan and issue of ordinary shares under the Company's Stock Incentive Plan.

It is expected that the new ordinary shares will be admitted to listing and to trading at 8:00 a.m. on 1 June 2011.

As a result of this issue of shares and in conformity with the Financial Services Authority's Disclosure and Transparency Rules, the Company gives notice that its voting capital consists of 118,484,530 Ordinary Shares of 5 pence each.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules.

Contacts:

Asterand plc

Martyn Coombs, Chief Executive Officer Tel: + 44 (0) 1763 211 600 /

+ 1 [phone]

John Stchur, Chief Financial Officer As above

Buchanan Communications

Lisa Baderoon / Mark Court / Isabel Podda Tel: [phone]

Daniel Stewart & Company plc

Antony Legge Tel: [phone]

Martin Lampshire Tel: [phone]

About Asterand

Asterand plc is a leading supplier of high quality human tissue and tissue-based services. Our comprehensive approach to human tissue and research services offers pharmaceutical, biotech and diagnostic companies the unique opportunity to have one company meet all of their human biomaterial needs along the continuum of drug discovery and development. Our mission is to accelerate target discovery and compound validation and enable pharmaceutical and biotechnology companies to take safer and more effective drugs into the market. For more information about Asterand, go to www.asterand.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOEDMGZKFKZGMZM